Bionpharma
Bionpharma, a leading biopharmaceutical company headquartered in the United States, has established itself as a key player in the development and manufacturing of complex generic and specialty pharmaceuticals. Founded in 2015, Bionpharma has rapidly expanded its operational footprint across major regions, focusing on delivering high-quality, affordable medications to patients worldwide. The company is renowned for its innovative approach to drug formulation and its commitment to quality, offering a diverse portfolio of products that includes injectables and oral dosage forms. Bionpharma's unique capabilities in complex generics position it favourably within the competitive landscape, enabling it to meet the evolving needs of healthcare providers and patients alike. With a strong emphasis on research and development, Bionpharma continues to achieve significant milestones, solidifying its reputation as a trusted partner in the biopharmaceutical industry.
DitchCarbon Score
How does Bionpharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bionpharma's score of 3 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bionpharma's reported carbon emissions
Bionpharma, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on climate change or their strategic approach to reducing carbon emissions. In the absence of specific emissions data, it is essential to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and carbon neutrality. Bionpharma may be engaging in similar efforts, aligning with industry trends towards reducing Scope 1, 2, and 3 emissions, although specific commitments or achievements have not been disclosed. As the industry evolves, stakeholders are encouraged to monitor Bionpharma's future announcements regarding their climate strategies and emissions reduction initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bionpharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
